Fanny Jaulin, PhD is cofounder, CEO&CSO of Orakl Oncology & Director of research Inserm/Gustave Roussy She has a PhD in cell biology (Univ. Marseille), post-doctorates in New York (Weill Cornell Medical center, Memorial Sloan Kettering Cancer Center). Researcher at Inserm, ATIP-Avenir laureate (2021), team leader at Gustave Roussy. Prix Fradiss de la fondation de France (2019). Business training (HEC, Challenge +, France, 2022). Cofounder and CEO/CSO of Orakl Oncology since 2022. Awarded for Orakl Oncology: MATWIN (2022), Unicancer (2023). Her previous work includes a strong scientific track record with publications in cell biology for oncology. She builds Gustave Roussy patient organoid expertise and managed institutional programs in organoid-based precision medicine (ORGANOTREAT clinical trials, RHU ORGANOMIC, Gustave Roussy organoid platform). She has raised 17 million€ in international public and private funding including more than 3 million€ for Orakl Oncology. As the current President (CEO) and Scientific Director (CSO) of Orakl Oncology, Fanny Jaulin leverages her unique scientific expertise, connection with the hospital and pharmaceutical industry thanks to her position at Gustave Roussy., as well as her skills in fundraising, project and team management. She led the creation of Orakl in January 2023 and its following 3M€+ fundraising.